INTRODUCTION
An inflammasome is a pro-inflammatory cytoplasmic structure formed upon detection of exogenous pathogen-associated or danger-associated molecular patterns (PAMPs/DAMPs). The inflammasomopathies describe a group of mechanistically related diseases, each, the result of inappropriate inflammasome activation. Inflammasomopathies can be protean disorders; for instance, activating mutations in the gene encoding NLR family pyrin domain containing 3 (NLRP3) may present with cold urticaria, or progressive hearing loss or neonatal onset multisystem inflammatory disease (NOMID) [1] .
In 2014, two groups independently identified gain-of-function mutations in the gene encoding NLR-family caspase activation and recruitment domain (CARD)-containing protein 4 (NLRC4) in four patients displaying recurrent, life-threatening episodes of autoinflammation and infantile enterocolitis (AIFEC) [2, 3] . Since that time, the identification of additional AIFEC patients and their successful treatment with targeted therapies have revealed important insights into AIFEC pathophysiology. Also, new reports have described additional clinical phenotypes associated with novel germline or somatic NLRC4 mutations. Herein, we summarize the growing body of literature describing NLRC4 mutation-associated autoinflammatory diseases, the NLRC4 inflammasomopathies.
NLRC4 INFLAMMASOME BIOLOGY
There are several canonical inflammasomes, and each is organized similarly: cytosolic PAMP/DAMP detectors are linked via an adaptor protein, apoptosis-associated speck-like protein containing a CARD (ASC), to the cleaved, active form of pro-caspase-1 [4] . Upon activation, the inflammasome rapidly forms a large wheel-shaped structure [5] , exhausting cellular ASC stores. Inflammasome formation initiates pyroptosis, a form of inflammatory cell death [6] and also proteolytically activates pro-interleukin 1 family cytokines (IL-1b and IL-18) into their cleaved, active forms [7] [8] [9] .
Inflammasome identity and specificity are determined by eponymous detector proteins, which include: absent in melanoma 2 (AIM2) [10] , NLRP3 [11] and NLRC4 [12] . Like the NLRP3 inflammasome, which responds to numerous cytosolic DAMPs/PAMPs [13] [14] [15] , the human NLRC4 inflammasome recognizes at least two bacterial ligands, flagellin and the type three secretion system (T3SS) [16] . NLRC4 is distinct from NLRP3 and AIM2 because it does not directly interact with its ligands. Instead, NLRC4 is activated via contact with the sensor protein NLR family of apoptosis inhibitory protein (NAIP), and it is NAIP that physically binds either flagellin or a T3SS [17] . This arrangement suggests NLRC4 might be better categorized as a scaffolding protein rather than a PAMP detector, although NLRC4 might also be considered an adaptor. Unlike NLRP3 and AIM2, NLRC4 contains a CARD allowing it to directly contact pro-caspase-1 without ASC [18] . Notably, absent ASC, the NLRC4 inflammasome is functionally altered favoring pyroptosis over cytokine production [3, 16] .
NLRC4 inflammasome biology has primarily been studied in myeloid cells including circulating monocytes and neutrophils but as NLRC4 detects components of lung and gut-trophic pathogens, its behavior in mucosal tissues is also of vital interest. Recently, a specialized host defense role of the NLRC4 inflammasome was identified in mouse intestinal epithelial cells (IECs). Upon detection of Salmonella spp. within IEC cytoplasm, the NLRC4 inflammasome rapidly forms producing IL-18 and diarrhea-causing eicosanoids [19 && ]. Instead of pyroptosis, Salmonella spp. containing IECs undergo IL-18-independent, caspase-dependent, nonlytic cell death with subsequent expulsion into the colonic lumen [20] . Although this adaptation produces secretory diarrhea, vascular leak and shock, it likely prevents catastrophic, invasive bacterial infections.
NLRC4 inflammasome initiation is exquisitely sensitive; a single ligand-bound NAIP molecule is sufficient to propagate NLRC4 oligomerization [21] , yet as systemic inflammation impacts host survival, the process is highly regulated. One level of regulation occurs intrinsically through the autoinhibitory structure of the NLRC4 molecule [22] . NLRC4 consists of a CARD, a ligand binding and NAIPinteracting leucine-rich repeat (LRR) and a regulatory nucleotide-binding oligomerization domain (NOD) (Fig. 1) [23] . Within the NOD, helical domain 1 (HD1), winged helix domain (WHD) and helical domain 2 (HD2) form a specialized adenosine diphosphate (ADP)-binding pocket that stabilizes NLRC4 in its inactive conformation [12, 22, 24] . Upon LRR detection of ligand-bound NAIP, the NOD undergoes a conformational change that promotes ADP for adenosine triphosphate (ATP) exchange, NLRC4 oligomerization and inflammasome assembly [22] . A second regulatory layer controls cytokine production and is inflammasome-extrinsic, as production of inactive pro-IL-1 family cytokines requires signals from cell surface PAMP/DAMP receptors including tumor necrosis factor (TNF) receptor 1 and toll-like receptor 4 (TLR4) [25] . Physiologically inert, these procytokines accumulate intracellularly until an inflammasome cleaves them into immunologically active compounds.
There are 11 IL-1 cytokine family members; only two, IL-1b and IL-18, are synthesized as inactive precursors [25] . IL-1b mediates the classic signs and symptoms of the febrile response. The IL-1 receptor binds to either IL-1b or its endogenously produced competitive inhibitor, IL-1 receptor agonist (IL-1RA) [26, 27] . Canonically, IL-18 amplifies lymphocyte functions, increasing cytotoxicity through IFNg production. Circulating IL-18 is
KEY POINTS
The NLRC4 inflammasomopathies are caused by gainof-function mutations in the gene encoding the innate immune protein NLRC4. Mutant NLRC4 promotes spontaneous formation of the NLRC4 inflammasome, production of IL1 family cytokines (IL-1b and IL-18) and inflammatory cell death.
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Rapid case identification using disease biomarkers like elevated serum IL-18 concentrations, characteristic skin biopsy findings and ultimately diagnostic gene sequencing, combined with timely application of immune modulatory therapy are key strategies to improving AIFEC patient outcomes.
sequestered by an endogenous-binding protein (IL-18BP), preventing receptor binding [25] . The full effects of IL-18 are incompletely understood, but recent work suggests IL-18 equilibrium controls intestinal barrier function in mice and that excessive free IL-18 potentiates colitis [28 && ].
AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS
In 2014, two investigative groups simultaneously and independently reported gain-of-function NLRC4 mutations in four patients from two unrelated families [2, 3] . The disease, called by one group as NLRC4 macrophage activation syndrome (NLRC4-MAS) and by the other as syndrome of enterocolitis and autoinflammation associated with mutation of NLRC4 (SCAN4), was later designated autoinflammation with infantile enterocolitis (AIFEC) by Online Mendelian Inheritance in Man (OMIM, #616050, Ã 606831) [29] . As the syndromes originally described by each team were remarkably similar and shared a common cause, we will use the umbrella term AIFEC, in this review, to avoid confusion and build consensus.
AIFEC is a chronic inflammatory disease punctuated by episodes of extreme acuity. All seven reported AIFEC patients have required hospitalizations in intensive care units during inflammatory episodes. Two infantile cases have been fatal. AIFEC flares have been appropriately compared with MAS; both entities share signature IL-1b symptomology (fever, tachycardia) and interferon gamma (IFNg)-related histopathology (hemophagocytosis). Peripheral blood transcriptional profiles generated from two AIFEC patients in flare suggest MAS-like myeloid cell activation and cytotoxic T-cell dysfunction [2, 30 && ]. In its most extreme form, an AIFEC flare can be confused with primary hemophagocytic lymphohistiocytosis (HLH), with hypertriglyeridemia, coagulopathy, multilineage cytopenias, elevated soluble IL-2 receptor and poor in-vitro cytotoxicity [2,3,30
Importantly, cytotoxic function normalizes in AIFEC patients after flares resolve, indicating intact granule-dependent cytotoxicity machinery. Another feature and useful biomarker distinguishing AIFEC from primary HLH is extremely elevated serum IL-18 concentrations (more than 10 4 pg/ml). IL-18 elevations of this degree are described in only a small cadre of inflammatory diseases including AIFEC, X-linked inhibitor of apoptosis (XIAP) deficiency and systemic juvenile idiopathic arthritis/adult-onset Stills disease-related MAS [33, 34] . The trigger for AIFEC flares is unknown. At least two older AIFEC patients experienced flares with physical and emotional stressors [3] . Another possible trigger could be activation of the mutant NLRC4 inflammasome with flagellin or T3SS expressing bacteria. In vitro, AIFEC macrophages infected with T3SS-expressing Salmonella spp. or Pseudomonas spp. form numerous altered assemblies of inflammasome components that favor pyroptosis over cytokine production [3] . Nonetheless, such bacteria have not yet been recovered from flaring AIFEC patients.
One area where MAS and AIFEC do not overlap is gastrointestinal disease. Diarrhea is an uncommon MAS symptom whereas severe, secretory, neonatal diarrhea is the most common AIFEC presentation. In one case, there is evidence AIFEC enterocolitis began in utero [ [2, 3, 30 && ], raising the possibility that mutant NLRC4 in IECs, not myeloid cells, is the primary driver of gut disease. Because of feeding intolerance, many AIFEC patients temporarily require parenteral nutrition, including the oldest known AIFEC patient, now 46 years old. His course was first described by Shwachman and coworkers in a 1973 case series of 16 infants with undifferentiated, protracted diarrhea supported by this nutritive method [36] . For this and other surviving AIFEC patients, symptomatic enterocolitis spontaneously normalized after the first year of life even though serum IL-18 concentrations remain persistently elevated into adulthood.
In addition to enterocolitis and MAS-like episodes, AIFEC patients can develop numerous organ-specific symptoms secondary to lymphohistocytic inflammation. For instance, ephemeral maculopapular and urticarial rashes associated with lymphohistiocytic infiltrates can occur (unpublished data). Astute clinicians may elect to biopsy and stain skin lesions in suspected AIFEC cases for rapid diagnostic information, as this histologic finding is unusual. Similarly, central nervous system dysfunction (obtundation, seizures) and hepatic dysfunction correlate with activated macrophages in related tissues [3, 31 & ]. AIFEC is caused by heterozygous NLRC4 gain-offunction mutations, which exhibit complete penetrance. There are now four published AIFEC-associated NLRC4 mutations: V341A, T337S, T337N and S171F (Table 1 and Fig. 1 ). The V341A variant is described in four individuals from two unrelated pedigrees, whereas the remaining variants occurred in single cases. Interestingly, the AIFEC patient harboring the S171F variant was mosaic for this allele. Although the variant accounted for only a quarter of NLRC4 peripheral blood transcripts, the patient's inutero disease onset and fatal outcome suggest it to be highly pathogenic. Amino acid positions 337 and 341 are both located in the autoinhibitory HD-1 subdomain of NOD. NLRC4 crystal structure analysis suggests that hydrophobic residues at position 341 are important for closing the 'lid' on the ADPbinding pocket to prevent ADP-ATP exchange [3, 22] . Similarly, position 337 may stabilize the pocket's tertiary structure through interactions with residues 170 and 173 or 173 only [2, 22] . Presumably, substitution of phenylalanine for serine at position 171 alters these interactions [31 & ]. Although infantile diarrhea and MAS-like episodes are the signature features of AIFEC, it is a chronic inflammatory disease. Patients surviving infancy are of short stature and exhibit anemia of chronic disease [3] . Between flares, untreated AIFEC patients display moderately elevated acute phase reactants and highly elevated serum IL-18 concentrations [2, 3] . Amyloidosis, a long-term complication of many untreated autoinflammatory disorders, has not yet been described in AIFEC patients but could be a concern. Longitudinal observation of surviving AIFEC pediatric cases and identification of more adult AIFEC cases may be informative.
EXTENDED NLRC4 PHENOTYPES
Shortly after publication of the original AIFEC cases, 13 members of a Japanese pedigree were reported with a syndrome of neonatal-onset fever, coldinduced urticarial rash and arthralgias [38] . A heterozygous NLRC4 H443P variant segregated with disease. Symptoms were sufficiently mild that most affected members did not require treatment. Serum IL-18 concentrations were not assessed, but patient cells exposed to cold in vitro spontaneously produced IL-1b. Given the clear phenotypic similarities to the NLRP3-associated familial cold autoinflammatory syndrome (FCAS1), OMIM designated this disease as FCAS4 (#616115; Ã 606831) [29] . In 2017, a second large Dutch kindred was reported with prominent skin manifestations [39 & ]. A heterozygous S445P NLRC4 variant segregated with disease. Like FCAS4 patients, these patients developed inflammatory symptoms early in life that did not significantly alter long-term survival; the eldest affected member was age 88 years. Uniquely, in these kindred, most patients developed conjunctivitis or uveitis, and many had a nodular and urticarial rash. Although affected individuals lacked MAS or infantile enterocolitis, two developed intestinal inflammation in adulthood. Functional studies of the S445P variant were not conducted, but many individuals displayed highly elevated serum IL-18 concentrations. Unlike FCAS1 patients whose biopsied skin lesions are characteristically neutrophilic [40] , skin infiltrates in Dutch patients' biopsies were lymphohistiocytic as seen in AIFEC [39 & ]. In addition to the traditional patterns of disease inheritance, two patients have been described with NLRC4 somatic mosaicism. One, discussed above, presented with prenatal AIFEC [31 & ], the other presented with cardinal NOMID features (fever, rash, inflammatory bone lesions, sensory neural hearing loss and structural brain defects) but he was NLPR3 mutation-negative and displayed chronically elevated serum IL-18 [37] . Functional analysis of patient pluripotent stem cell-derived monocytes revealed two distinct populations, one with aberrant and the other with normal IL-1b secretion. The aberrant IL-1b producing cells harbored a novel T177A NLRC4 variant. Notably, this mutation was initially missed on whole exome sequencing analysis.
It is unclear how gain-of-function mutations in the same gene can produce such disparate clinical phenotypes, but a genotype/phenotype relationship may exist. The FCAS phenotype appears to correlate with WHD subdomain variants (H443P and S445P), whereas AIFEC and NOMID associate with HD-1 and NBD subdomain variants (S171F, T177A, T337S, T337N and V341A) (Fig. 1) . Recent functional work suggests pathologic NLRC4 variants in WHD may differentially promote caspase 8-mediated cell death whereas variants in HD-1 do not [41] .
TREATMENT OF NLRC4 INFLAMMASOMOPATHIES
Although all NLRC4 inflamasomopathies are categorically autoinflammatory disorders, they manifest across a broad severity spectrum. Without a NLRC4-specific therapy, treating physicians have chosen to target downstream inflammatory mediators based upon their patients' clinical needs. For instance, many patients with FCAS4 were well controlled with only nonsteroidal anti-inflammatory drugs or nothing at all [39 & ]. Other non-AIFEC patients were treated with recombinant IL-1RA (anakinra) and although skin manifestations were completely responsive, other disease features were not. Anakinra was also highly effective in treating NOMIDlike symptoms because of NLRC4 mutation [37] . Used prophylactically, anakinra reduced the severity and frequency of MAS episodes more effectively than low-dose steroids and colchicine in one AIFEC patient with mild gastrointestinal disease [2] , but was not efficacious treating another AIFEC patient in flare [30 && ]. The most therapeutically challenging AIFEC manifestations are MAS and enterocolitis. Sadly, NLRC4 mutations were found posthumously in several patients with overwhelming neonatal AIFEC, and their aggressive presentation and rapid progression clouded assessment of treatment efficacy [3,31 & ]. MAS episodes were managed successfully with corticosteroids, cyclosporine and IVIg in at least one adult patient prior to his AIFEC diagnosis [3] . Notably, this same patient has experienced prolonged periods of treatment-free quiescence between life-threatening MAS flares.
Several agents specifically targeting deranged AIFEC immunologic pathways are under development. For example, we observed dramatic efficacy using recombinant IL-18BP in a critically ill neonatal AIFEC patient whose disease was refractory to combined corticosteroids, cyclosporine, IL-1 inhibition, TNF-inhibition and integrin-inhibition [ . As such, early gut colonization may promote excessive IL-1 family cytokine production in AIFEC patients. Likewise, spontaneous resolution of AIFEC enterocolitis may coincide with maturation of the gut, mucosal immunity and/or the adoption of a less inflammatory microbiota [42] . Without more data, we cannot recommend either intestinal decontamination or fecal transplantation in AIFEC patients. Similarly, as NLRC4 is expressed in both myeloid and intestinal epithelia cells, we would not anticipate hematopoietic stem cell transplantation by itself or intestinal transplantation by itself, would be curative.
CONCLUSION
The NLRC4 inflammasomopathies constitute a growing category of autoinflammatory diseases that span a broad clinical spectrum from cold urticaria to NOMID and the often-fatal disease AIFEC. Since 2014, 34 patients have been reported with NLRC4 gain-of-function mutation-associated diseases. Of these, most are from two unrelated families with NLRC4 variants that do not appear to confer a significant survival disadvantage.
There are seven published case studies of AIFEC patients; two were fatal cases and all the patients experienced significant morbidity due, in part, to diagnostic delay. Even now that it has been established as a distinct clinical entity, AIFEC continues to pose a diagnostic challenge because most cases are sporadic. Accordingly, early recognition of telltale AIFEC symptoms and a rapid diagnosis, using disease biomarkers like serum IL-18 concentrations, characteristic skin biopsy findings and ultimately gene sequencing, will be paramount to improving disease outcomes. Likewise, the timely implementation of anti-inflammatory therapies, either already approved (anakinra, steroids, IVIg, cyclosporine) or available through ongoing clinical trials (recombinant IL-18BP; NCT03113760 or anti-IFNg monoclonal antibodies; NCT02069899), will continue to be a key determinate of survival.
